Correction To: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated With Darunavir

Drugs in R and D- United Kingdom

doi 10.1007/s40268-018-0243-y

Full Text

Abstract

Available in

Categories

Date

August 6, 2018

Authors

Dessislava Dimitrova

Johan Verspeelt

Simon Vanveggel

Kimberley Brown

Christiane Moecklinghoff

Richard E. Nettles

Publisher

Springer Science and Business Media LLC

Related search

Thyroid Evaluation in HIV-1-infected Patients

Journal of Venomous Animals and Toxins Including Tropical Diseases

Infectious Diseases

English

An Audit of Cardiovascular Disease Risk Management in HIV-infected Patients Attending a Northern English Hospital

Journal of the International AIDS Society

Infectious Diseases

Occupational Health

English

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Clinical Journal of the American Society of Nephrology

Transplantation

Intensive Care Medicine

English

Pharmacokinetics of Darunavir/Ritonavir in Asian HIV-1 Infected Children Aged >=7 Years

Antiviral Therapy

Infectious Diseases

English

Evaluation of Cardiovascular Biomarkers in HIV-infected Patients Switching to Abacavir or Tenofovir Based Therapy

BMC Infectious Diseases

Infectious Diseases

English

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged≥3 to <12 Years

CPT: Pharmacometrics and Systems Pharmacology

Cardiovascular Medicine

English

HIV and Cardiovascular Disease: Contribution of HIV-Infected Macrophages to Development of Atherosclerosis

Molecular Biology

English

Perivascular Fat, Inflammation, and Cardiovascular Risk in HIV-infected Patients on Antiretroviral Therapy

International Journal of Cardiology

Cardiovascular Medicine

English

Correction of Metabolic Disorders in Patients Co-Infected With HIV/HCV

English